LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 28 April 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that new data evaluating its lead product, EndoBarrier®, will be presented during two upcoming medical meetings.

New research evaluating EndoBarrier and its potential mechanism of action will be presented during an oral presentation at Digestive Disease Week 2014 (DDW), taking place May 3-5, 2014 in Chicago. In addition, new data demonstrating EndoBarrier’s effect on insulin requirements in patients with type 2 diabetes will be presented during a poster session at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific & Clinical Congress to be held May 14-18, 2014 in Las Vegas.

The schedule for EndoBarrier presentations at DDW is as follows:

Date & Time: Monday, May 5 at 8:30 a.m. CT

Session: The GI Tract and Obesity

Title: Duodenojejunal Bypass Liner Increases Fasting and Postprandial Serum Levels of Bile Acids in Patients with Severe Obesity

Abstract Number: 589 

Location: McCormick Place – S106A

Presenter: Rodrigo Munoz, M.D., Ph.D., Department of Digestive Surgery, Pontificia Universidad Catolica School of Medicine 

The schedule for EndoBarrier presentations at AACE is as follows:

Date & Time: Thursday, May 15 from 10-11 a.m. PT

Session: Obesity

Title: Rapid Reduction in Insulin Requirements in Patients with T2DM Following Implantation of an Endoscopically-Placed Duodenojejunal Bypass Liner (EndoBarrier)

Abstract Number: 705

Location: Exhibit Hall, Paris Las Vegas Hotel

Presenter: Tim Ramacciotti, M.D., MPH, Senior Lecturer, School of Medicine at the University of Notre Dame Australia

About GI Dynamics

GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier®, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.

Forward-Looking Statements

This announcement contains forward-looking statements concerning: our development and commercialization plans; our potential revenues, costs, profitability and financial performance; our ability to obtain reimbursement for our products; our clinical trials, and associated regulatory submissions and approvals; the number and location of commercial centres offering the EndoBarrier®; and our intellectual property position.  These forward-looking statements are based on the current estimates and expectations of future events by the management of GI Dynamics, Inc. as of the date of this announcement and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements.  These risks and uncertainties include, but are not limited to: risks associated with the possibility that clinical trials will not be successful or confirm earlier results; risks associated with obtaining funding from third parties; risks relating to the timing and costs of clinical trials, results of clinical trials, the timing of regulatory submissions, the timing and receipt of regulatory approvals, the timing and amount of other expenses; execution risks; competition; risks related to market acceptance of products; intellectual property risks; and assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches, future financial results and other factors.  Given these uncertainties, you should not place undue reliance on these forward-looking statements.  We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.